A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for12 weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
Year: 2006
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
Year: 2007
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
A randomised, double-blind, placebo-controlled study of the efficacy and safety of a diclofenac sodium patch for the topical treatment of acute pain due to mild to moderate soft tissue injuries.
Year: 2009
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
Open-label study to evaluate the Long-Term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects with Non-malignant Pain.
Year: 2010
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
A confirmatory, placebo-controlled, randomised, double-blind, single dummy, parallel group, ratio-finding study in constipated pain patients to establish an optimal Hydromorphone – naloxone ratio with an improved bowel function and a comparable analgesic efficacy compared to Hydromorphone alone.
Year: 2011
Type: Pharmaceutical - Pain
Phase: II, III
Indication: Pain - General
A randomised, double-blind, double-dummy, parallel-group multicentre study to demonstrate improvement in symptoms of constipation and noninferiority in analgesic efficacy in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy taking 50/25 – 80/40 mg twice daily as oxycodone/naloxone prolonged release (OXN PR) tablets compared to subjects taking 50 – 80 mg twice daily oxycodone prolonged release (OxyPR) tablets alone.
